Literature DB >> 28882711

Stereotactic Radiosurgery of Central Skull Base Meningiomas-Volumetric Evaluation and Long-Term Outcomes.

Mohana Rao Patibandla1, Cheng-Chia Lee2, Jason Sheehan3.   

Abstract

BACKGROUND AND
OBJECTIVE: Complete resection of a central skull base meningioma (CSM) is possible, but it is often associated with high morbidity. Stereotactic radiosurgery (SRS) plays an appreciable role in the management of skull base meningiomas. This study aims to apply volumetric methods to assess the CSM response after SRS and correlate it with clinical outcomes.
MATERIALS AND METHODS: The cohort consisted of 219 patients, of whom 73.9% were female (n = 162), with a median age of 55 years (19-88). SRS was the primary treatment for 45.7% (n = 100), while 37.9% (n = 83) underwent treatment for residual tumors, 14.2% (n = 31) for recurrence, and in 5 with others reasons. The median tumor volume was 4.9 cm3 (0.3-105 cm3) to a median margin dose of 14 Gy (5-35 Gy). Volumetric analysis of CSM was performed on the SRS scan and each available magnetic resonance image thereafter.
RESULTS: The median clinical and imaging follow-ups of the cohort were 72 (24-298) and 66 (18-298) months, respectively. The overall tumor control rate was 83.4% (n = 183) at last follow-up with tumor regression 72.1% (n = 158). Neurologic symptoms were improved after SRS in 6.8% (n = 15), stable in 72.6% (n = 159), and worsened in 20.5% (n = 45). The clinical deterioration usually occurred in the patients with tumor progression (P < 0.001). Following SRS, the volumetric analysis confirmed that tumor response at 3 years reliably projected volumetric change and tumor control at 5 years (R2 = 0.694) with P < 0.001 and 10 years (R2 = 0.571) with P = 0.001.
CONCLUSION: SRS affords effective tumor volumetric control and neurologic stability or improvement in the majority of patients with CSMs. The radiologic response of CSM as determined by volumetry at 3 years post-SRS is predictive of long-term tumor response at 5 and 10 years following SRS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Central skull base; Gamma Knife; Meningioma; Middle fossa; Parasellar; Petroclival; Stereotactic radiosurgery; Volumetry

Mesh:

Year:  2017        PMID: 28882711     DOI: 10.1016/j.wneu.2017.08.166

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Meningiomas: skull base versus non-skull base.

Authors:  Torstein R Meling; Michele Da Broi; David Scheie; Eirik Helseth
Journal:  Neurosurg Rev       Date:  2018-04-07       Impact factor: 3.042

2.  The long-term outcome of CyberKnife-based stereotactic radiotherapy for central skull base meningiomas: a single-center experience.

Authors:  Sukwoo Hong; Kengo Sato; Kenji Kagawa; Shunsuke Ichi
Journal:  Neurosurg Rev       Date:  2021-04-10       Impact factor: 3.042

3.  Skull Base Meningiomas in Patients with Neurofibromatosis Type 2: An International Multicenter Study Evaluating Stereotactic Radiosurgery.

Authors:  Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gautam U Mehta; Gregory P Lekovic; Jason P Sheehan
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

Review 4.  Ten-year follow-up after Gamma Knife radiosurgery of meningioma and review of the literature.

Authors:  Bodo E Lippitz; Jiri Bartek; Tiit Mathiesen; Petter Förander
Journal:  Acta Neurochir (Wien)       Date:  2020-06-26       Impact factor: 2.216

Review 5.  Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

Authors:  Riccardo Laudicella; Domenico Albano; Salvatore Annunziata; Diletta Calabrò; Giovanni Argiroffi; Elisabetta Abenavoli; Flavia Linguanti; Domenico Albano; Antonio Vento; Antonio Bruno; Pierpaolo Alongi; Matteo Bauckneht
Journal:  Cancers (Basel)       Date:  2019-09-22       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.